Kenya Advances Local Vaccine Technology

S 1 - 2 - 3 D I ID RK RT C - 0

Kenya BioVax Institute reported that locally manufactured vaccines will enter trial production by 2027 as enabling works continue at the Embakasi biotechnology plant. Officials said the first output will include pneumonia vaccines for newborns, produced through platforms aligned with global standards. The project expands Kenya’s biomedical capacity, with the facility expected to deliver six million doses monthly. World Bank partners noted the initiative supports Africa’s broader goal to increase regional pharmaceutical technology and production.